AKBA Akebia Therapeutics Inc.

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Nik Grund, Chief Commercial Officer, will participate in a Fireside Chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14 at 10:00 AM EDT.

A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at following the conference.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at , which does not form a part of this release.

Akebia Therapeutics Contact

Mercedes Carrasco



EN
08/07/2025

Underlying

AKBAAkebia Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Akebia Therapeutics Inc.

 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidne...

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Nik Grund, Chief Commercial Officer, will participate in a Fireside Chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14 at 10:00 AM EDT. A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at following the conference....

July 8, 2025 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rul...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 141,800 shares of Akebia’s common stock on June 30, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise...

July 1, 2025 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Publ...

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology Akebia continues to publish important, clinically relevant data to further physicians’ understanding of Vafseo® (vadadustat) CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the (JASN) has published pre-specified analyses for the U.S. and non-U.S. patient subgroups from the vadadustat global phase 3 clinical program, whic...

June 4, 2025 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rul...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 137,000 shares of Akebia’s common stock on May 30, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise...

June 2, 2025 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conf...

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025 CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Akebia Executive Management will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on Thursday, June 5 at 8:45 AM EDT. A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at following the conference. The Jefferies Global Healthcare Conferenc...

May 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch